	US 12,454,728 B2
	Compositions and methods for amplifying, detecting or quantifying human cytomegalovirus
Paul Darby, San Diego, CA (US); Siobhan Miick, San Diego, CA (US); Jo Ann Jackson, Lakeside, CA (US); Hee Cheol Kim, San Diego, CA (US); Amber Hillius, San Diego, CA (US); and Ankur Shah, San Diego, CA (US)
Assigned to Gen-Probe Incorporated, San Diego, CA (US)
Appl. No. 17/269,775
Filed by Gen-Probe Incorporated, San Diego, CA (US)
PCT Filed Aug. 21, 2019, PCT No. PCT/US2019/047419 § 371(c)(1), (2) Date Feb. 19, 2021, PCT Pub. No. WO2020/041414, PCT Pub. Date Feb. 27, 2020.
Claims priority of provisional application 62/720,658, filed on Aug. 21, 2018.
Prior Publication US 2022/0074002 A1, Mar. 10, 2022
Int. Cl. C12P 19/34 (2006.01); C12Q 1/70 (2006.01)

CPC C12Q 1/705 (2013.01) [C12Q 2600/158 (2013.01)]

17 Claims

1. A kit for amplifying a target region of nucleic acid derived from a human cytomegalovirus (CMV) UL56 gene sequence comprising:

(a) a forward primer comprising 20-31 contiguous nucleobases present in SEQ ID NO: 2 and comprising the nucleobase sequence of SEQ ID NO:11;

(b) a reverse primer comprising 23-40 contiguous nucleobases present in SEQ ID NO: 3 and comprising the nucleobase sequence of SEQ ID NO:23; and

(c) a probe oligomer comprising one or more detectable labels, wherein the probe oligomer hybridizes to a CMV amplicon generated by the forward and reverse primers.